Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: telaprevir
Drug: ribavirin
Biological: peginterferon alfa-2a

First Posted Date: 2008-09-23

Last Posted Date: 2021-03-26

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 540

Registration Number: NCT00758043

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Biological: Pegylated Interferon Alfa 2a
Drug: Ribavirin
Drug: Telaprevir
Other: Placebo

First Posted Date: 2008-03-04

Last Posted Date: 2014-08-08

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 1095

Registration Number: NCT00627926

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: VCH 916
Drug: Placebo

First Posted Date: 2008-02-26

Last Posted Date: 2014-04-04

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 42

Registration Number: NCT00623649

Locations: 🇵🇷
Fundacion de Investigacion de Diego, Santurce, Puerto Rico
🇨🇦
Royal Victoria Hospital, Montréal, Quebec, Canada
🇺🇸
The Liver INstitute at Methodist Dallas, Dallas, Texas, United States

and more 2 locations

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: Telaprevir
Drug: Ribavirin
Drug: Pegylated interferon alfa 2a

First Posted Date: 2007-09-26

Last Posted Date: 2014-08-05

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 117

Registration Number: NCT00535847

Locations: 🇺🇸
Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸
South Denver Gastroenterology, Englewood, Colorado, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

and more 38 locations

Study of Telaprevir in Subjects With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Insufficiency

First Posted Date: 2007-07-31

Last Posted Date: 2008-10-29

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Registration Number: NCT00509210

Locations: 🇺🇸
Indiana University, Department of Medicine,Division of Gastroenterology / Hepatology, Indianapolis, Indiana, United States

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

Phase 1

Completed

Conditions: Spinal Cord Injury

Interventions: Drug: Cethrin

First Posted Date: 2007-07-13

Last Posted Date: 2016-04-14

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 48

Registration Number: NCT00500812

Locations: 🇺🇸
Univ.of Virginia Health System, Charlottesville, Virginia, United States
🇨🇦
Sunnybrooke Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦
Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada

and more 5 locations

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: AVN944

First Posted Date: 2007-06-28

Last Posted Date: 2020-09-30

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 28

Registration Number: NCT00493441

Locations: 🇺🇸
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States

and more 13 locations

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Ivacaftor 25 mg/75 mg
Drug: Ivacaftor 75 mg/150 mg
Drug: Ivacaftor 150 mg or 250 mg
Drug: Placebo

First Posted Date: 2007-04-09

Last Posted Date: 2012-10-05

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 39

Registration Number: NCT00457821

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
The Children's Hospital, Aurora, Colorado, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

and more 12 locations

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: Telaprevir
Drug: Ribavirin
Drug: Matching Placebo
Drug: Pegylated Interferon Alfa 2a

First Posted Date: 2007-01-11

Last Posted Date: 2014-08-05

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 465

Registration Number: NCT00420784

Locations: 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇺🇸
University of Florida, Gainesville, Florida, United States

and more 31 locations

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Phase 2

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2006-11-03

Last Posted Date: 2007-12-07

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 120

Registration Number: NCT00395577

Locations: 🇸🇮
Call For Information, Ljubljana, Slovenia
🇵🇱
Call for Information, Torun, Poland

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy